
Journal	<i>Hypertension</i>	Manuscript #	HYPE201914137R1
Date	25-Oct-2019 16:01 GMT	IP Address	138.26.111.69
Title	Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension		
Authors	Mohammed Siddiqui, Eric Judd, Tanja Dudenbostel, Pankaj Gupta, Maciej Tomaszewski, Prashanth Patel, Suzanne Oparil, and David Calhoun		

Instructions for Authors Conflict of Interest Disclosure

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form includes the questions from the International Committee of Medical Journal Editors (ICMJE) Form for Disclosure of Potential Conflicts of Interest and is divided into 6 subsections. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information.

Authors are expected to provide detailed information about all relevant financial interests, activities, relationships, and affiliations (other than those affiliations listed in the title page of the manuscript) including, but not limited to, employment, affiliation, funding and grants received or pending, consultancies, honoraria or payment, speakers bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents and copyrights planned, pending, or issued.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor

receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer. Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so. For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc

Other: Anything not covered under the previous 3 boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Section 1. Identifying Information

Author: Suzanne Oparil

Date: 25-Oct-2019

I am the Corresponding Author

Manuscript Title: Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension

Manuscript Identifying Number: HYPE201914137R1

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc)?

Yes

1. NIH/NHLBI R01 HL113004
grants
Co-Investigator, R01 Mechanisms of Refractory Hypertension

Section 3. Relevant Financial Activities Outside the Submitted Work

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use 1 line for each entity; add as many lines as you need by clicking the "Add" button to add a row. Excess rows can be removed by pressing the "Remove" button. You should report relationships that were **present during the 36 months prior to submission**.

Yes

1. Pfizer, Inc
personal fees
Consultant; ACC/AHA Guideline Webinar
2. Medtronic, Inc
personal fees
Member, Expert Strategic Advisory Meeting Medtronic RDN
3. ROX Medical, Inc
personal fees
ROX Control HTN 2 Study – US IDE
4. CinCor
personal fees
Scientific Advisory Board (2019) primary
5. Preventric Diagnostics, LLC
other
Medical & Technology Committee
6. Bayer
grants
site PI-diabetic kidney disease
7. Idorsia Pharmaceuticals

Co-Investigator, multicenter study Phase 3 study

8. Novartis
site PI-resistant HTN

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents or copyrights, whether planned, pending, or issued, broadly relevant to the work?

No

Section 5. Relationships Not Covered Above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

Editor-in-Chief, Current Hypertension Reports (Journal; Publisher – Springer Science Business Media LLC); annual stipend of \$5,000 (Springer); Editor-in-Chief Term until 12/2020

At the time of manuscript acceptance, the journal will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, the journal may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement in the box below after you click the “Generate Disclosure Statement” button. Any subsequent changes will also update the disclosure statement automatically after clicking the “Submit” button.

Dr Oparil reports grants from NIH/NHLBI R01 HL113004 during the conduct of the study; personal fees from Pfizer, Inc, personal fees from Medtronic, Inc, personal fees from ROX Medical, Inc, personal fees from CinCor, other from Preventic Diagnostics, LLC, and grants from Bayer outside the submitted work; and Editor-in-Chief, Current Hypertension Reports (Journal; Publisher - Springer Science Business Media LLC); annual stipend of \$5,000 (Springer); Editor-in-Chief Term until 12/2020.

By completing this form, I confirm that the information reported is accurate. I understand that, where appropriate, this information may be disclosed publicly. I further understand that the American Heart Association, Inc., reserves the right to decline to publish my work if the Organization believes a significant conflict of interest exists.

Suzanne Oparil

Checking this box acts as your signature for the Authors Conflict of Interest Disclosure Questionnaire.

25-Oct-2019 16:01 GMT

local_p_id: 2965

time: 1572020142

ip address: 138.26.111.69